In a significant Texas probate ruling, an appeals court has affirmed summary judgment in favour of executors, finding the plaintiffs’ claims were barred by the statute of limitations. The case, Conover v.
Maryland’s Family and Medical Leave Insurance program is approaching a critical implementation milestone, with contribution requirements set to take effect on January 1, 2027. The FAMLI program requires employers and employees to
More
HSBC Holdings (LSE: HSBA) has delivered one of the most impressive performances among FTSE 100 banks, with its share price surging 60% over the past 12 months to reach 1,528p. That gain
More
Bank of England Governor Andrew Bailey has warned that advanced artificial intelligence models could trigger a disorderly correction in global financial markets. Bailey issued the warning in a two-page letter published Monday
More
Gillian Anderson, best known for her roles in Sex Education and The X-Files, has made a new investment into women’s football through Crux Football. Crux Football is a Europe-based multi-club ownership group
More
Cencora’s senior director of manufacturer operations and data services, Ameer Ali, is raising the alarm over the scale of disruption that the pharmaceutical industry faces in transitioning to the 12-digit NDC format.
More
Two major developments in California are reshaping how businesses face legal exposure over common website tracking technologies like cookies and pixels. On August 21, 2026, the California Court of Appeal issued a
More
Rep. James Clyburn appeared on “Meet the Press” this weekend and made an admission that politicians rarely offer: he was wrong about Clarence Thomas. The confession carries particular weight for Clyburn because
More
Citi analysts have identified US cell tower companies as likely beneficiaries if SpaceX moves forward with broader Starlink terrestrial network infrastructure buildout. The bank’s research suggests demand for tower infrastructure could rise
More
IP Group has attracted fresh scrutiny from value-focused investors, with the intellectual property commercialisation firm flagged as among the cheapest stocks on the FTSE 250. The London-listed company, which trades under the
More
PharmaEssentia has secured a significant regulatory milestone as the FDA approved a label expansion for its rare blood cancer drug Besremi, known generically as ropeginterferon alfa-2b-njft. The drug, first approved by the
More